Related Experiment Videos
Spirocyclic NK(1) antagonists II: [4.5]-spiroethers.
Brian J Williams1, Margaret A Cascieri, Gary G Chicchi
1Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, UK. brian_williams@merck.com
Bioorganic & Medicinal Chemistry Letters
|September 10, 2002
Summary
Researchers developed new spiroether compounds targeting neurokinin-1 (NK1) receptors. These novel antagonists show high affinity and effectively penetrate the central nervous system (CNS).
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Neurokinin-1 (NK1) receptors are implicated in various neurological and psychiatric disorders.
- Developing selective NK1 antagonists is a key therapeutic strategy.
Purpose of the Study:
- To design and synthesize novel spiroether-based compounds as potential NK1 antagonists.
- To investigate the structure-activity relationships (SAR) of these compounds.
- To identify compounds with high affinity and optimal central nervous system (CNS) penetration.
Main Methods:
- Synthesis of a series of novel spiroether derivatives.
- Evaluation of binding affinity for the NK1 receptor.
- Assessment of CNS penetration properties through in vitro and/or in vivo models.
Main Results:
- Several novel spiroether-based compounds were successfully synthesized.
- Modifications to the spiroether ring and aromatic substituents significantly impacted NK1 receptor affinity.
- Identified lead compounds demonstrated high affinity and excellent CNS penetration capabilities.
Conclusions:
- Spiroether scaffolds are promising for the development of potent NK1 antagonists.
- Strategic modifications can optimize both receptor affinity and CNS bioavailability.
- These findings provide a foundation for further development of NK1 antagonists for CNS-related conditions.